<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0807</journal-id>
<journal-title><![CDATA[Revista de la Universidad Industrial de Santander. Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Univ. Ind. Santander. Salud]]></abbrev-journal-title>
<issn>0121-0807</issn>
<publisher>
<publisher-name><![CDATA[Universidad Industrial de Santander]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-08072025000100013</article-id>
<article-id pub-id-type="doi">10.18273/saluduis.57.e:25v57a10</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia y factores asociados a eventos adversos por dipirona y tramadol intravenoso en pacientes hospitalizados de ortopedia: estudio transversal analítico en un hospital de Medellín 2010-2020]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence and Associated Factors of Adverse Events from Intravenous Dipyrone and Tramadol in Hospitalized Orthopedic Patients: An Analytical Cross-Sectional Study in a Hospital in Medellín, 2010-2020]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Angulo-Castañeda]]></surname>
<given-names><![CDATA[Nancy Yaneth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Audor-González]]></surname>
<given-names><![CDATA[María Helena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil-Castrillón]]></surname>
<given-names><![CDATA[Norman Alfonso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castaño-Arias]]></surname>
<given-names><![CDATA[Paula Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Herrera]]></surname>
<given-names><![CDATA[Gilma Norela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas-Bernal]]></surname>
<given-names><![CDATA[Luz Angela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Alma Máter de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria del Área Andina  ]]></institution>
<addr-line><![CDATA[Bogotá D.C ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Cardenal Herrera-CEU  ]]></institution>
<addr-line><![CDATA[Castellón ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>57</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-08072025000100013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-08072025000100013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-08072025000100013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Dipirona y tramadol son analgésicos utilizados con frecuencia en la hospitalización de ortopedia, el primero fue retirado del mercado en algunos países por el reporte de eventos adversos como la agranulocitosis, y el segundo se ha relacionado con anafilaxia y depresión respiratoria.  Objetivo: Establecer la prevalencia y los factores asociados a eventos adversos por dipirona y tramadol intravenoso en pacientes hospitalizados en el servicio de ortopedia de un hospital en Medellín durante los años 2010 a 2020; estos datos fueron recolectados y analizados de acuerdo a las historías clínicas de cada paciente.  Metodología: Estudio transversal analítico de fuente secundaria de 973 registros, 253 con reacciones adversas y 720 sin reacción adversa.  Resultados: La prevalencia de reacciones adversas fue de 17,47% para Dipirona y 8,53% para tramadol, encontrando un IC al 95 para la diferencia entre la proporción de reacciones adversas por Dipirona menos tramadol de (5,90% - 12,00%). Se presentaron 3,16% reacciones serias, 3,53% por dipirona y 2,41% por tramadol, siendo evitables 2,94% para dipirona y 2,41% para tramadol. Los factores asociados a reacciones adversas fueron la duración de uso de tramadol más de 7 días (OR=5,71; IC95%:3,96-8,24) y los diagnósticos de infección (OR=1,96; IC95%:1,15-3,15), radiculopatía (OR=2,16; IC95%:1,19-3,92) y traumatismo (OR=3.43; IC95%:1,64-7,19).  Conclusiones: Es necesario reforzar la farmacovigilancia activa que permita identificar eventos adversos y factores de riesgo asociados. Se recomienda diseñar protocolos y guías de práctica clínica para el uso de dipirona y tramadol intravenoso en los servicios intrahospitalarios de ortopedia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Dipyrone and tramadol are analgesics frequently used in orthopedic hospitalization, the first was withdrawn from the market in some countries due to reports of adverse events such as agranulocytosis, and the second has been related to anaphylaxis and respiratory depression.  Objectives: To establish the prevalence and factors associated with adverse events due to intravenous dipyrone and tramadol in patients hospitalized in the orthopedic service of a hospital in Medellín during the years 2010 to 2020; these data were collected and analyzed according to the clinical histories of each patient.  Methodology: Analytical cross-sectional study of secondary source of 973 records, 253 with adverse reactions and 720 without adverse reaction.  Results: The prevalence of adverse reactions was 17.47% for dipyrone and 8.53% for tramadol, finding a 95% CI for the difference between the proportion of adverse reactions for dipyrone less tramadol of (5.90% -12,00%). 3.l6% serious reactions occurred, 3.53% for dipyrone and 2.4l% for tramadol, with 2.94% for dipyrone and 2.4l% for tramadol being avoidable. Factors associated with overall adverse reactions were duration of use of tramadol more than 7 days (OR=5.71; IC95%:3.96-8.24) and diagnoses of infection (OR=l.96; IC95%:1.15-3.15), radiculopathy (OR=2.16; IC95%:1.19-3.92) and trauma (OR=3.43; IC95%:1.64-7.19).  Conclusions: It is necessary to reinforce active pharmacovigilance to identify adverse events and associated risk factors. It is recommended to design protocols and clinical practice guidelines for the use of intravenous dipyrone and tramadol in in-hospital orthopedic services.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Dipirona]]></kwd>
<kwd lng="es"><![CDATA[Tramadol]]></kwd>
<kwd lng="es"><![CDATA[Analgésicos]]></kwd>
<kwd lng="es"><![CDATA[Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Ortopedia]]></kwd>
<kwd lng="es"><![CDATA[Tiempo de Internación]]></kwd>
<kwd lng="es"><![CDATA[Estudios de Corte Transversal]]></kwd>
<kwd lng="en"><![CDATA[Dipyrone]]></kwd>
<kwd lng="en"><![CDATA[Tramadol]]></kwd>
<kwd lng="en"><![CDATA[Analgesics]]></kwd>
<kwd lng="en"><![CDATA[Drug-Related Side Effects and Adverse Reactions]]></kwd>
<kwd lng="en"><![CDATA[Orthopedics]]></kwd>
<kwd lng="en"><![CDATA[Length of Stay]]></kwd>
<kwd lng="en"><![CDATA[Cross Sectional Studies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jasiecka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maslanka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jaroszewski]]></surname>
<given-names><![CDATA[JJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological characteristics of metamizole]]></article-title>
<source><![CDATA[Pol J Vet Sci]]></source>
<year>2014</year>
<volume>17</volume>
<page-range>207-14</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverry]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current controversies on the clinical use of dipyrone: safe alternative?]]></article-title>
<source><![CDATA[Colomb J Anesthesiol]]></source>
<year>2019</year>
<volume>47</volume>
<page-range>261-3</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Tompkins]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NSAIDs Safe? Assessing the Risk-Benefit Profile of Nonsteroidal Anti-inflammatory Drug Use in Postoperative Pain Management]]></article-title>
<source><![CDATA[Am Surg]]></source>
<year>2021</year>
<volume>87</volume>
<page-range>872-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Sistema de Tramites en Línea - Consultas Públicas</collab>
<source><![CDATA[Consulta datos de productos]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Cárdenas]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
<name>
<surname><![CDATA[Laverde-Gaona]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Cabarique-Serrano]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Cháves-Rojas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Reina-Sierra]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Infante]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the incidence of adverse events related to the administration of dipyrone]]></article-title>
<source><![CDATA[Colomb J Anesthesiol]]></source>
<year>2018</year>
<volume>46</volume>
<page-range>119-25</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Duarte]]></surname>
<given-names><![CDATA[OG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is it time to restrict the clinical use of dipyrone?]]></article-title>
<source><![CDATA[Colomb J Anesthesiol]]></source>
<year>2019</year>
<volume>47</volume>
<page-range>81-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Trejos]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Morales]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Ramírez]]></surname>
<given-names><![CDATA[LF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identificación de reacciones adversas medicamentosas en pacientes tratados con dipirona en un hospital de tercer nivel]]></article-title>
<source><![CDATA[Ces Med]]></source>
<year>2019</year>
<volume>33</volume>
<page-range>13-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamerschlak]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maluf]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eluf-Neto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalcanti]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of aplastic anemia and agranulocytosis in Latin America: the LATIN study]]></article-title>
<source><![CDATA[Sao Paulo Med J]]></source>
<year>2005</year>
<volume>123</volume>
<page-range>101-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barakat]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisiting Tramadol: A Multi-Modal Agent for Pain Management]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2019</year>
<volume>33</volume>
<page-range>481-501</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rios]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Erquiaga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Errasti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol: ruleta analgésica]]></article-title>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2020</year>
<volume>27</volume>
<page-range>1-65</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mico]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Berrocoso]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery and development of tramadol for the treatment of pain]]></article-title>
<source><![CDATA[Expert Opin Drug Discov]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>1281-91</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Freking]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dallman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heddings]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postoperative Pain Management with Metamizole after Orthopedic Surgery: A Systematic Review]]></article-title>
<source><![CDATA[Kans J Med]]></source>
<year>2024</year>
<volume>17</volume>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fornasier]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Francescon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An historical overview over Pharmacovigilance]]></article-title>
<source><![CDATA[Int J Clin Pharm]]></source>
<year>2018</year>
<volume>40</volume>
<page-range>744-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución 3100 de 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>Gobernación de Antioquia. República de Colombia</collab>
<source><![CDATA[Vigilancia sanitaria a medicamentos y afines]]></source>
<year></year>
<publisher-name><![CDATA[Programa Departamental de Farmacovigilancia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[EJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and types of preventable adverse events in elderly patients: population based review of medical records]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>320</volume>
<page-range>741-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaitán-Duarte]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Eslava-Schmalbach]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Malagon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Forero-Supelano V Santofimio-Sierra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Altahona]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidencia y evitabilidad de eventos adversos en pacientes hospitalizados en tres instituciones hospitalarias en Colombia, 2006]]></article-title>
<source><![CDATA[Rev Salud Pública]]></source>
<year>2008</year>
<volume>10</volume>
<page-range>215-26</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Beninger P Pharmacovigilance: An Overview</collab>
<source><![CDATA[Clin Ther 2018]]></source>
<year></year>
<volume>40</volume>
<page-range>1991-2004</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Resolución Número 8430 DE 1993]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia Del Campo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Murcia Soler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Mir]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Palop]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adequacy of the safety of metamizole and agranulocytosis]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2021</year>
<volume>53</volume>
<page-range>102047</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parra Díaz]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
</person-group>
<source><![CDATA[Análisis del perfil de seguridad del metamizol en españa]]></source>
<year></year>
<publisher-name><![CDATA[Universidad de Valladolid]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Momenté]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Pranchevicius]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil]]></article-title>
<source><![CDATA[BMC Pharmacol Toxicol]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno De Santacruz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Buitrago]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Pérez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de dipirona en pacientes hospitalizados]]></article-title>
<source><![CDATA[Rev Repert Med Cir]]></source>
<year>2013</year>
<volume>22</volume>
<page-range>204-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhagudu]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Erravalli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol-Related Adverse Drug Reactions at an Addiction Psychiatry Setting: A Cross-Sectional Analysis]]></article-title>
<source><![CDATA[Indian J Psychol Med]]></source>
<year>2019</year>
<volume>41</volume>
<page-range>593-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Vaca]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[MF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events associated with tramadol and dipirona administration in a level III hospital]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>369-81</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zazzara]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vetrano]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Carfí]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Onder]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions in older adults: a narrative review of the literature]]></article-title>
<source><![CDATA[Eur Geriatr Med]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>463-73</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Barquilla P Velasco]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Pacheco]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions in internal medicine units and associated risk factors]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2010</year>
<volume>66</volume>
<page-range>1257-64</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uzzaman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chapter 28: Classification of hypersensitivity reactions]]></article-title>
<source><![CDATA[Allergy Asthma Proc]]></source>
<year>2012</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aronson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Susceptibility to adverse drug reactions]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2019</year>
<volume>85</volume>
<page-range>2205-12</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tribiño]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bustamante]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de las potenciales interacciones farmacológicas en pacientes de una unidad de cuidados intensivos en un hospital de tercer nivel de Bogotá]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2018</year>
<volume>38</volume>
<page-range>407-16</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
